Fig. 6: Regulation of lipolysis and MASLD development via manipulating Golgi PtdIns4P–CUL7FBXW8–ATGL axis.
From: Glucose controls lipolysis through Golgi PtdIns4P-mediated regulation of ATGL
a, Immunoblot of ATGL protein in the liver from hepatocyte-specific Pi4kb knockout mice 2 weeks after AAV8 administration (n = 8 mice per group). b, Immunoblot of ATGL protein in the liver from hepatocyte-specific Cul7 and Fbxw8 knockout mice 2 weeks after AAV8 administration (n = 6 mice per group). c, Immunoblot of ATGL protein in the liver 1 h after 2-DG injection under the background of Cul7 and Fbxw8 double knockout in the hepatocytes (n = 6 mice per group). d, Determination of hepatic TG levels in NCD feeding mice 4 weeks after AAV8 administration or HFD feeding mice 8 weeks after AAV8 administration (n = 10 mice per NCD group and 5 mice per HFD group). e,f, H&E and ORO staining to the liver from hepatocyte-specific Pi4kb (e), Cul7 and Fbxw8 (f) knockout mice under NCD and HFD feeding conditions. Scale bar, 200 μm. Representative images from five mice per group with similar results. g, Determination of hepatic TG levels in hepatocyte-specific Cul7 and Fbxw8 knockout mice fed in NCD and HFD after AAV8 administration (n = 11 mice per NCD group and 5 mice per HFD group). h, Schematic illustration of experimental design to administer UCB9608 to wild-type mice. i, Plasma FFA levels in wild-type mice 8 weeks after administration of DMSO and UCB9608 (n = 12 mice per group). j, Hepatic TG levels in DMSO- and UCB9608-treated mice (n = 15 mice per group). k, H&E and ORO stainings to the liver from DMSO- and UCB9608-treated mice. Scale bar, 200 μm. Representative images from ten mice per group with similar results. Data are presented as mean ± s.e.m. and analysed using two-tailed unpaired t-test (a, c, d and j), two-tailed Mann–Whitney test (i) and one-way ANOVA method with Dunnett correction for multiple comparisons between control and other groups (b and g). Source numerical data and unprocessed blots are available in .
